CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
Active, not recruiting · NCT05162976 · Registry updated 2026-06-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma | Active, not recruiting | Phase 1 | 2026-06-03 | NCT05162976 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| City of Hope Medical Center | 347 |
| National Cancer Institute (NCI) | 3015 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Medical Center | Duarte | United States | 313 |